EURORDIS - Rare Diseases Europe
    Newsletter
December 2007

 

In this issue
  • IN BRIEF
  • EDITORIAL
  • NEWS: 29 February 2008: First European Rare Disease Day
  • INSIGHT: Noteworthy results for the third Eurordis patient survey
  • AROUND EUROPE: Denmark: a focus on social services for rare disease patients
  • LIVING WITH A RARE DISEASE: Living in a tall world
  • ORPHAN DRUGS

  •  
    EDITORIAL
    Dear Readers,

    There is one thing Santa Claus or anyone else cannot do for you, and that you must write down, right now, at the top of your Christmas list: " I shall write my contribution to the Public Consultation on the Commission Communication on Rare Diseases" before Christmas and send it to the Commission"! This Public Consultation has now been launched at the European Conference on Rare Diseases 2007 Lisbon on 26-27 November and is ongoing for 8 weeks.

    You think it's not really any of your business? You don't feel competent enough? Think it's only in English? A bureaucratic exercise? Your contribution will have little impact? You feel it takes too much time? I am sorry to tell you that you're getting it all wrong!

    The Draft Commission Communication is a text of about 20 pages and it will be translated in over 20 LANGUAGES to make it easy to read and assess by everyone. 10 QUESTIONS are listed: you can answer all of them, or only a few-or even just one. You can make comments or write a short letter of support. And you can write in any of these 20 languages. EVERYONE and ANYONE can send feedback to this public consultation... And probably ALL READERS of this Newsletter should be personally or professionally concerned enough to spare a few moments to write a contribution.

    As its name indicates, the Communication concerns all rare diseases, from the rarest to the most frequent or best known. It is intended to cover all possible policy on rare diseases: research, medicines and other products, healthcare organisation, information, social support, patient groups; and encompasses promotion of policies both at community and national levels. All stakeholders are invited to send a contribution: patient groups, researchers, health care and social professionals, industry, Member States AND ANY CITIZEN can send his or her personal views. Contributions from individuals or organisations from European countries which are not EU Member States are very welcome, as are those from other parts of the world.

    All contributions received by the European Commission will be published on their website and a synthesis will be prepared in conjunction with the DG Sanco Rare Disease Task Force. The final version of the Communication will take into account these contributions and shall be adopted before year end 2008.

    A "text" alone will not save lives? A text boosting rare disease policies and actions can save lives if it creates the right public health framework. Rare diseases are a new public health concept to address the needs of millions of people struggling with unmet medical needs. It is still a malleable field where every new policy or action, even those with limited resources, has a strong and structuring impact, and high return. Because of the rarity of our diseases, the added value of European Community action is exceptionally high. This Communication is one more step to gain social recognition, unleash energies and create new solutions throughout Europe. It is already a step in saving lives.

    Yann Le Cam
    Chief Executive Officer

     

     
    NEWS: 29 February 2008: First European Rare Disease Day
    A day for rare diseases? Yes, it is happening! 29 February 2008 will be the first celebration of the European Rare Disease Day: A Rare Day for Very Special People. The organisation of this awareness Day is coordinated by Eurordis at the European level and by National Alliances at the national level. Many events will take place throughout Europe. The Rare Disease Day will happen every year from 2008 onward.

     
    INSIGHT: Noteworthy results for the third Eurordis patient survey
    The preliminary results of EurordisCare3, the third Eurordis survey on rare disease patient access to care, were presented at the European Workshop on Centres of Expertise and Reference Networks for Rare Diseases held in July 2007 in Prague. The survey aimed at describing and comparing the experiences and expectations of patients and their families in regards to access to health services for 16 rare diseases in Europe. The preliminary results are introduced in this article. Advanced results were presented at ECRD 2007 Lisbon.

     
    AROUND EUROPE: Denmark: a focus on social services for rare disease patients
    Rare Disease patients in Denmark enjoy high-quality social and education services. Although the Danish healthcare system is decentralised, there are two specialised treatment centres for rare diseases in the country. People living with rare diseases still face some problems, which organisations such as Rare Disorders Denmark, the Danish national alliance for rare diseases, are fighting. And Copenhagen will host Eurordis's next Annual Membership Meeting on May 16-17, 2008.

     
    LIVING WITH A RARE DISEASE: Living in a tall world
    Marco has achondroplasia, a bone growth disorder that is characterised by a type of dwarfism. This 40- year-old Italian business consultant tells us about his life in a world made for people with a "regular" height.

     
    ORPHAN DRUGS

    New designations October 07

     

    Treatment of acute myeloid leukaemia
    Amonafide L-malate

    Treatment of Leber's congenital amaurosis
    Adenovirus associated viral vector serotype 4 containing the human RPE65 gene

    Treatment of chronic lymphocytic leukaemia
    Alvocidib

    Treatment of Herpes simplex virus stromal keratitis
    Ciclosporin

    Treatment of non-traumatic osteonecrosis
    Human autologous bone-forming cells derived from bone marrow stem cells

    Treatment of idiopathic pulmonary fibrosis
    Interferon gamma

    Treatment of glioma
    Iodine (131I) chlorotoxin

    Treatment of Gaucher Disease
    Isofagomine tartrate

    Treatment of acute lymphoblastic leukaemia
    Methotrexate (oral liquid)

    Treatment of acute lymphoblastic leukaemia
    Mercaptopurine (oral liquid)

    Treatment of hepatocellular carcinoma
    4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid

     

     

    All Orphan Drugs in Europe (in English) >

    European Public Assessment Reports (EPARs)(multilingual) >


     


    The Eurordis E-Newsletter is made possible thanks to the generous funding of The Medtronic Foundation.

    Editorial Team: Yann Le Cam, Jérôme Parisse-Brassens, Julia Fitzgerald, Nathacha Appanah (Writer), Anja Helm, François Houÿez

    Translation Team: Conchi Casas Jorde (Spanish), Ana Cláudia Jorge and Victor Ferreira (Portuguese), Roberta Ruotolo (Italian), Trado Verso (French), Ulrich Langenbeck (German)

    © 2007 Eurordis


     
    IN BRIEF
     
    Events

     

    Lowe Syndrome Second International Symposium
    7 Dec. 2007
    London, UK

    Rare Disease March
    8 Dec. 2007
    Paris, France

    Evaluation & Use of Medicinal Products during Pregnancy
    A 3-day intensive course at Geneva University Hospital
    13-15 Dec. 2007
    Geneva, Switzerland

    IAPO Global Patients Congress 2008
    20-22 February 2008
    Budapest, Hungary

    Rare Disease Congress in Latin America - ER2008LA
    27-29 March 2008
    Buenos Aires, Argentina

    ICORD 2008: 4th International Conference on Rare Diseases and Orphan Drugs
    ""Global Approaches for Rare Diseases Research and Orphan Products Development"
    20-22 May 2008
    Washington D.C., USA

     

    More events
    2007 | 2008 >

    Eurordis welcomes new members

    Full Membership

    Ichthyosis België
    Belgium
    www.devidts.com
    Represents: Ichthyosis

     

    See all Eurordis member organisations >

     

    News in brief
     

    The 500th Orphan Drug was designated last September. This represents a milestone for the rare disease world. The designation of orphan drugs started in 2000 and they all undergo a single centralised procedure for marketing authorisation at European level. The 500th orphan drug is intended for the treatment of Leber's congenital amaurosis.

    Quick Links...

    More About Us

    Our Members

    Our Activities & Projects

    Donate

    News Archive

    Subscribe to Newsletter

    On-line Communities

    Orphan Drug Information

    OrphaNews Europe: Newsletter



     
    phone: +33 1 56 53 52 10
     

     

            Eurordis - European Organisation for Rare Diseases | 102 rue Didot | 75014 PARIS | France

     

          <----back

     

     
    Privacy & Disclaimer Newsletter

     

    AISMME

    Home
    Messaggio di AISMME
    Finalità
    Progetti
    Aiuta AISMME
    Contatti

    Malattie Metaboliche Ereditarie

    Descrizione
    Centri di Cura
    SOS
    Links Utili

    Attività

    Iniziative
    Incontri
    Rassegna Stampa
    Supporters

    INFO

    News
    Congressi
    Legislativa
    Libreria